bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
Published 3 years ago • 84 plays • Length 1:29
Download video MP4
Download video MP3
Similar videos
-
3:41
teclistamab: bcma x cd3 bispecific antibody in rrmm
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
5:28
regn5459, a bcma×cd3 bispecific antibody, in r/r multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
11:05
3mensio ct pre-case planning: tavr with alternate access (axillary/subclavian)
-
6:48
alfred garfall: evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
3:18
midiagnostics' complete blood count (cbc) - blood analysis for diagnosis and monitoring
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
3:34
exciting results for bcma/cd3 bispecific pf-3135 in r/r mm
-
3:30
sc vs. iv administration of a bcma-cd3 bispecific antibody for r/r myeloma
-
2:25
first-in-human study of talquetamab: a gprc5d-cd3 bispecific antibody for r/r mm
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:38
a phase i study of wvt078, a bcma×cd3 bsab, with a gamma-secretase inhibitor (whg626) in r/r mm
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
2:36
the latest on teclistamab
-
4:15
talquetamab: gprc5d-cd3 bispecific antibody in r/r myeloma
Clip.africa.com - Privacy-policy